UKPOL.CO.UK

Tag: Lord Walton of Detchant

  • Lord Walton of Detchant – 2016 Parliamentary Question to the Department of Health

    Lord Walton of Detchant – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Walton of Detchant on 2016-03-01.

    To ask Her Majesty’s Government whether appropriate treatment for patients with plasma disorders such as haemophilia and primary immunodeficiency, as provided for under the statutory scheme for branded medicines, will continue to be provided following the review of that scheme by the Department of Health.

    Lord Prior of Brampton

    We are continuing to consider carefully all the consultation responses. It is important we get these changes right for patients, the National Health Service and industry. We want to look in particular at the impact on small and medium sized businesses, while securing the medicines patients need at a cost which the NHS can afford.

  • Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Walton of Detchant on 2014-06-10.

    To ask Her Majesty’s Government what assessment they have made of the impact of the proposals for value-based assessments published by the National Institute for Healthand Care Excellence on 22 March 2014 on patients’ access to new cancer medicines.

    Earl Howe

    A consultation on the National Institute for Health and Care Excellence’s (NICE) proposals for value assessment is ongoing and no decisions have yet been made about any potential changes to NICE’s methods of technology appraisal.

    The consultation will close on 20 June and we would encourage all those with an interest, including patients, clinicians, the National Health Service, industry, researchers and academic experts, to make their views known as part of this process.

  • Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Walton of Detchant on 2014-06-10.

    To ask Her Majesty’s Government what effect the new proposals for value-based assessments published by the National Institute for Healthand Care Excellence on 22 March 2014 have had on the availability of treatments to patients with (1) those forms of cancer which are more frequent in older people, and (2) rare types of cancer.

    Earl Howe

    A consultation on the National Institute for Health and Care Excellence’s (NICE) proposals for value assessment is ongoing and no decisions have yet been made about any potential changes to NICE’s methods of technology appraisal.

    The consultation will close on 20 June and we would encourage all those with an interest, including patients, clinicians, the National Health Service, industry, researchers and academic experts, to make their views known as part of this process.

  • Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Walton of Detchant on 2014-06-10.

    To ask Her Majesty’s Government what estimate they have made of the uptake of innovative anti-coagulant medicines in the management of venous thromboembolism in the National Health Service.

    Earl Howe

    Decisions on the prescribing of medicines are a matter for clinicians in discussion with their patients.

    Dabigatran (Pradaxa), apixaban (Eliquis) and rivaroxaban (Xarelto) are recommended in National Institute for Health and Care Excellence (NICE) technology appraisal guidance for use in reducing the risk of venous thromboembolism (VTE)after hip or knee replacement surgery. Rivaroxaban is also recommended as a treatment option for adults with deep vein thrombosis and in the prevention of recurrent deep vein thrombosis and pulmonary embolism. National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

    NHS England has advised that it is working with the Health & Social Care Information Centre as part of the National VTE Prevention Programme to analyse the uptake of medicines in this area.

    The Health and Social Care Information Centre’s report on the Use of NICE appraised medicines in the NHS in England 2012, published on 21 January 2014, includes information on the usage of dabigatran etexilate, apixaban and rivaroxaban for prevention of venous thromboembolism after hip or knee replacement surgery in secondary care.

    The report showed an increase in mean usage over time during 2010-2012 and an increase in the total use of the drugs over time, which had accelerated in 2012. The report is available at:

    www.hscic.gov.uk/catalogue/PUB13413/use-nice-app-med-nhs-exp-stat-eng-12-rep.pdf

  • Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    Lord Walton of Detchant – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Walton of Detchant on 2014-06-10.

    To ask Her Majesty’s Government what steps they are taking to ensure access to innovative medicines in order to improve the management of venous thromboembolism in the National Health Service.

    Earl Howe

    The National Institute for Health and Care Excellence (NICE) has recommended a number of treatments for the prevention of venous thromboembolism. National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

    We understand that NHS England has established an Innovation Programme which ensures the commissioning system promotes and supports participation of the NHS in research, translating scientific developments into benefits for patients.